Critical illness is characterised by catabolism of the skeletal muscle that releases amino acids for protein synthesis to support tissue repair, immune defence and inflammatory and acute-phase responses. Protein requirements for these patients have generally been based on levels that result in the lowest catabolic rates or most favourable nitrogen balance. The definition of these levels, in particular, in relation to indexing to a measure of patient weight or lean body mass, is controversial. Furthermore, optimal nitrogen balance may not necessarily equate to best clinical outcome. There is some evidence that administration of specific amino acids may be advantageous at least during the early or most catabolic phases of illness, in order to support the specific amino acid requirements of the metabolic pathways activated by the injury or infection. Current widely used guidelines differ in the protein prescription they recommend and in the timing of administration in relation to intensive care admission. A pressing need exists for well-designed randomised trials that compare differing levels of protein or amino acid provision, and the timing of this provision, for their effects on clinical endpoints.
INTRODUCTION
Finely regulated metabolic adaptations allow healthy individuals to sustain prolonged periods of starvation. These include, when starvation extends beyond 2-3 days, a stimulation of ketogenesis and ketone body oxidation with the suppression of protein breakdown and gluconeogenesis. In contrast, in critically ill patients these adaptations do not occur, and accelerated protein-calorie malnutrition ensues, with increased risk of infection and compromised recovery unless nutritional support is instituted.
From an evolutionary standpoint, the redistribution of amino acids from skeletal muscle to visceral organs that characterises the metabolic response to major injury and/or infection provides a mechanism to enhance survival. Along with mobilisation of fat stores to provide energy, auto-cannibalisation of muscle tissues provides the precursors for synthesis of acute-phase proteins, for gluconeogenesis, and for immune and antioxidant defences. Without external support, the patient may survive with resolution of the inflammation, or more likely, succumb to sequelae of the systemic inflammatory response and the inexorable wasting of functional muscle tissue that occurs.
Modern intensive care allows supportive measures that can alleviate the adverse consequences of major injury/infection, and thereby improve survival of patients who would otherwise die. In particular, artificial feeding with appropriate macronutrients may reduce the muscle catabolism that is observed. Shaw et al.
1 and Shaw and Wolfe 2 carried out whole-body protein turnover studies using isotopically labelled amino acids in both severely septic and major traumatic injury patients who had been established on total parenteral nutrition (PN) for 7-10 days. They showed that net catabolism can be reduced significantly by the provision of total intravenous feeding (Figure 1 ). Although nutritional support increased the rate of protein synthesis, the rate of protein breakdown was unaffected.
Using body composition methodology, we have carried out energy balance studies over the 10 days soon after Intensive Care Unit (ICU) admission. 3, 4 In severely septic patients admitted to the ICU with peritonitis, accretion of total body fat occurred in patients in positive energy balance, while lipolysis was seen in those in negative balance (Figure 2 ). However, there was no correlation between the extent of protein catabolism and energy balance. Notwithstanding the evidence that adequate energy provision early in the course of critical illness may impact favourably on hospital mortality 5 , there appears to be a disconnect between energy requirements and protein losses.
The 'quality' and the dose of protein that should be provided to critically ill patients, and whether this dose should be dependent on the timing of its provision has been and remains the subject of considerable controversy.
WHAT PROTEIN AND WHAT DOSE?
Reprioritization of the normal nutritional homoeostasis of the body occurs in response to the hypermetabolism and catabolism of the systemic inflammatory response. Marked alterations in carbohydrate, fat and protein metabolism occur. The breakdown of muscle protein is required in part to fuel synthesis of the positive acute-phase proteins, and this may exceed 1 g/kg per day. 6 The amino acid composition of these proteins differs markedly from that of skeletal muscle (or typical dietary protein) with relatively higher levels of the aromatic amino acids, phenylalanine, tyrosine and tryptophan. 6 Phenylalanine content of C-reactive protein, for example, is 105 g/kg, while in typical animal skeletal muscle it is only 40 g/kg. To support the demand for phenylalanine, tyrosine and tryptophan during the acutephase response requires mobilisation of muscle protein (if this is the only source of amino acids) in quantities that greatly exceed those of the acute-phase proteins. Reeds et al. 6 have calculated that in a typical postsurgical acute-phase response, this excess muscle catabolism equates to a nitrogen loss of 0.13 g/kg per day, an amount similar to that seen, for example, after total colectomy. 7 In a septic rat model, increased demand for cysteine, threonine, serine and aspartate-asparagine was seen, and muscle wasting was reduced by dietary supplementation with these amino acids. 8 A number of the acute-phase proteins are rich in threonine, serine and asparagine. 6 Cysteine is important for glutathione synthesis, the most important intracellular antioxidant, and in infection and injury it may become indispensible. In a small (n ¼ 12) doubleblind study of patients with multiple trauma, addition of a mixture of cysteine, threonine, serine and aspartate to the enteral feed tended to improve muscle protein synthesis compared with the group receiving an isonitrogenous feed supplemented with alanine. 9 The provision of normal dietary protein to the highly catabolic patient would be expected to lead to excess amino acids that are not required for the acute-phase response. As Stroud 10 points out, this excess may not be harmless. Free amino acids that are not incorporated into protein must be metabolised, mostly to urea, which may be concerning in patients with renal impairment, a relatively common situation in the ICU.
A case can be made for tailoring the amino acid composition of feeds provided to ICU patients at least in the early or most catabolic phases of their illness. This may not only permit lower protein intake than would usually be prescribed using standard feeds, but at the same time spare muscle protein to a greater degree. One approach is to provide supplements containing specific amino acids early after admission to the ICU and independently of the usual feeding protocols. Beale et al.
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randomized 55 predominantly medical ICU patients to a glutamine-containing supplement or control supplement within 24 h of admission, which was continued for up to 10 days independently of enteral feeding starting on day 2 in accordance with feeding regimens of the ICU. Sequential organ failure assessment scores fell more rapidly in the glutamine group. However, this group received an immunonutrient-containing enteral feed in contrast to the control group, which received a standard feed so that it is difficult to draw conclusions regarding the relative merits of the supplement and the immunonutritional feed.
In general, the issue of how much protein to feed critically ill patients has relied on a few published studies using standard feeds and focused essentially on measurements of protein turnover, nitrogen balance or whole-body protein by neutron activation, rather than clinical outcome. Our work 12 using the latter approach is widely cited in this context, and suggested that protein catabolism over a 10-day period soon after ICU admission was reduced by 50% when protein intake increased from an average of 1.1 to 1.5 g/kg of 'dry' fat-free mass (FFM) per day. A higher level of protein intake (1.9 g/kg per day) did not confer any additional protein-sparing advantage. Nonprotein calorie intake did not differ between the three groups and averaged 29 kcal/kg 'dry' FFM per day. While a normally-hydrated FFM could be considered an ideal reference, this measure is generally inaccessible in the intensive care environment. The 'optimum' protein intake found by Ishibashi et al.
12 equates to 1.2 g per day per kg of 'dry' body weight, and this weight could be regarded as preadmission or 'normal' weight. That study, however, was a retrospective subgrouping of prospectively collected data on major trauma and severely septic patients and reported averages over 10 days. These methodologic shortcomings 13 are a real concern. However, this study was the only study cited in the recent systematic review of studies of protein intake in critical illness 14 that described how the protein or amino acid dose was calculated from body weight. This important consideration, given the profound effects of fluid overload on body weight in critical illness, means that between-study comparisons are problematic.
Weijs et al. 15 have suggested, estimating FFM from age, height, sex and actual body weight, or when overhydration/oedema is a concern, from preadmission weight so that protein may be prescribed at 1.5 g/kg FFM/per day, which these authors consider as the ideal target. This estimation equation was derived from the relationship between per cent body fat, age, sex and body mass index (BMI) established in a large group of healthy individuals (BMI range: 16-36). 16 It is of interest to examine this protein prescription, and others, in patients for whom we have detailed information on body weight, body fat and fluid status. Figure 3 shows results from our study of 12 patients admitted to the ICU with severe sepsis and followed for 21 days. 4 Study day 0 was a median 2 days after admission. Both body weight and FFM have been corrected to normally-hydrated ('dry') FFM, so that the difference between the upper two curves reflects the excess fluid in these patients and the difference between the lower two curves corresponds to the total fat mass. Corrected weight and FFM at Protein for the critically ill patient LD Plank day 0 would be expected to be close to preadmission weight and FFM. For these patients, the corrected FFM at day 0 is 45.6 kg, which compares well with the 46.7 kg given by the Weijs et al
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FFM formula using corrected weight. At 1.5 g/kg FFM, the daily protein target therefore equates to 68-70 g. Corrected weight at day 0 is 63.0 kg so that a protein target of 76 g per day is indicated using the 1.2 g/kg 'dry' body weight (or preadmission weight) recommendation.
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The ESPEN guidelines for PN in the ICU 17 recommend 1.3-1.5 g protein or amino acids per kg ideal body weight (IBW) per day. A formula for calculating IBW was not suggested and many such formulae have been developed. 18 The Devine equation 19 is one such, which is often used in the ICU and yields an IBW of 60.3 kg for the 12 sepsis patients, or 78-90 g protein per day based on the ESPEN targets. The American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines for nutrition support in adult critically ill patients 20 recommend protein provision of 1.2-2 g/kg actual body weight per day for patients with BMIo30. At an actual body weight of 79.4 kg on day 0 in our sepsis study this recommendation yields 95-159 g per day, a substantially higher band than the ESPEN recommendation. In contrast, the NICE guidelines 21 specifically recommend starting enteral or parenteral feeding at p50% of estimated target energy and protein needs, building up to full requirements over the first 1-2 days, without detailing how these target requirements might be determined. The Canadian guidelines, 22 also widely referred to, similarly do not make specific recommendations on protein and energy targets.
WHEN SHOULD IT BE DELIVERED?
For critically ill patients with a functioning gastrointestinal tract the ESPEN, 23 ASPEN 20 and Canadian 22 guidelines recommend early enteral nutrition (EN) within 24-48 h of admission or injury in patients who are haemodynamically stable, increasing to target energy goals over the subsequent 2-3 days. If these targets are not reached, the ESPEN guidelines recommend starting PN while the ASPEN guidelines, for patients with no evidence of malnutrition at admission, suggest withholding PN for 7 days if EN is not available for this period after admission. The Canadian guidelines (which are due to be updated in 2013) do not advocate initiating PN with EN in those patients for whom EN is suitable and, owing to lack of evidence, do not make a recommendation as to when PN should be started if EN is inadequate. The NICE 21 guideline recommendation that nutrition support should start at p50% of their estimated target energy and protein needs reflects the reality in respect of the delivery of calories by the enteral route in the ICU. This was borne out by the observational study of nutritional therapy in 162 ICUs worldwide, 24 where actual calorie delivery by the enteral route over the first 2 weeks of ICU admission was only about 50% of that prescribed.
It is also of interest to note that the recently published randomised trial (EPaNIC) comparing early PN initiation (ESPEN guidelines) with late initiation (ASPEN guidelines) resulted in protein delivery in both arms of the study that was considerably below recommended levels. 25 Median protein provision was less than 1 g/kg per day on every day of the 15 days of observation. For the early PN group 0.8 g/kg was reached on day 3 and for the late-PN group, median protein provision barely reached 0.3 g/kg on day 7. In this study, patients in the late-PN group had fewer ICU infections and a greater likelihood of being discharged alive earlier from the ICU. Contrasting results were obtained in another supplemental PN trial (TICACOS), 5 where hospital mortality was lower in the intervention group receiving targeted nutrition delivery guided by indirect calorimetry compared with standard nutrition delivery. The intervention group received some 600 kcal per day more than the standard group and protein intake, dictated by the enteral and parenteral feeds used, was 76 g per day (B1 g/kg per day) compared with 53 g per day (B0.7 g/kg per day). Notably, the EPaNIC trial was carried out in a relatively low mortality patient group compared with the TICACOS trial; ICU mortality in the former averaged 6.2% and in the latter 25.4%. Neither trial achieved the protein delivery targets recommended by the ESPEN and ASPEN guidelines.
Clinical outcome data are needed from randomised trials, in which protein delivery according to currently accepted targets is achieved. This may require not only PN as an adjunct to EN, but supplemental amino acids as well. Aggressive early feeding by the enteral route with protein supplements, if required to meet protein delivery targets, was shown to be feasible and safe in a pilot before and after study. 26 Hypocaloric feeding in the early phase of illness in conjunction with 'adequate or appropriate' amino acid delivery may be more important than achieving energy targets during this period. These trials should be directed at the highly catabolic, high mortality risk patient. 27 
CONCLUSIONS
The evidence for clinical benefit from protein delivery based on currently accepted targets as expressed in widely used guidelines is poor. Randomised clinical trials comparing differing levels of protein provision on clinical endpoints are sorely needed, without energy overfeeding as has been the case in many of the studies reviewed by Hoffer and Bistrian, 14 and with due regard for appropriate weight-indexing, taking account, if necessary, of fluid overload and excessive adiposity. While provision of an appropriate balance of amino acids may reduce net muscle catabolism, improvement in clinical outcome should be the primary focus of future trials.
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